glp-1 companies Analogues Transform Metabolic Disease Management | Mahesh Malhotra posted on the topic GLP-1 Check In - Citrini

This new complaint, along with a few others, centers on vision loss, alleging that Novo Nordisk failed to adequately warn users about the risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition characterized by reduced blood flow to the optic nerve

In March 2025, the FDA declared the end of the national shortage of approved GLP-1 drugs and gave online sellers until May 22 to withdraw mass-produced compounded versions from the market

When those underlying conditions are stable, medication adjustments are more likely to produce durable metabolic results

Until now, Medicare beneficiaries have had to pay out of pocket for the obesity drugs, costing them potentially hundreds of dollars a month

GLP-1 Receptor Agonist Use Linked to Higher Risk for Ischemic Optic Neuropathy THURSDAY, July 16, 2026 -- Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a higher risk for ischemic optic neuropathy (ION) compared with

Additionally, further investigations proved that a blockade of GLP-1R could result in the GFR reduction and NHE3-mediated sodium reabsorption enhancement in the proximal tubule (100)